Rockefeller Financial Services Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 24.8% during the second quarter, Holdings Channel reports. The fund owned 82,866 shares of the company’s stock after selling 27,302 shares during the period. Rockefeller Financial Services Inc.’s holdings in Johnson & Johnson were worth $10,962,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the company. Lenox Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at $117,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares during the last quarter. Ullmann Financial Group Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at $186,000. Finally, Taylor Wealth Management Partners increased its stake in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares during the last quarter. 66.06% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.02% during mid-day trading on Thursday, hitting $133.26. The stock had a trading volume of 1,484,359 shares. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The firm has a 50 day moving average of $133.23 and a 200 day moving average of $126.11. The stock has a market cap of $357.67 billion, a price-to-earnings ratio of 22.55 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.74 earnings per share. On average, analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.
COPYRIGHT VIOLATION WARNING: “Rockefeller Financial Services Inc. Has $10.96 Million Stake in Johnson & Johnson (NYSE:JNJ)” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/2800633/rockefeller-financial-services-inc-has-10-96-million-stake-in-johnson-johnson-nysejnj.html.
Several brokerages have recently weighed in on JNJ. UBS AG reaffirmed a “buy” rating and issued a $136.00 target price on shares of Johnson & Johnson in a research report on Monday, May 15th. BTIG Research cut Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target on the stock. in a research note on Friday, July 21st. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $140.00 price target on shares of Johnson & Johnson in a research note on Friday, June 16th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $133.72.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.